Concerns Surrounding Use of AI Dermatology Mobile Apps: Study

Artificial Intelligence Dermatology Apps Raise Concerns, Study Finds

In a recent study published in JAMA Dermatology, researchers have identified notable concerns surrounding the use of currently available artificial intelligence (AI) dermatology mobile applications (apps). The study, conducted by Shannon Wongvibulsin, M.D., Ph.D., and colleagues from the University of California in Los Angeles, found that many of these AI apps lack regulatory approval, supporting evidence, input from clinicians, and transparency in their development.

The researchers initially identified 909 AI dermatology apps, but after excluding duplicates and conducting further reviews, they focused on 41 apps for detailed analysis. None of these apps were approved by the U.S. Food and Drug Administration, and only two included disclaimers for lack of regulatory approval. Additionally, the apps lacked transparency in terms of algorithm development, data usage, and user privacy.

According to the authors, the use of these AI dermatology apps poses risks due to the lack of consistent validation and transparent user communication. They emphasize the importance of increasing awareness of these limitations and the need for further development of methods for creating AI dermatology apps with effective regulation, validation, and standardized evaluation criteria.

It is crucial for users to be aware of the potential risks associated with using AI dermatology apps and to exercise caution when relying on them for skin health concerns. Further research and regulation are needed to ensure the safety and effectiveness of these apps in the future.

For more information on this study, you can access the abstract and full text in JAMA Dermatology. Stay informed and stay safe when using AI dermatology apps.